Detalles de la búsqueda
1.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Br J Haematol
; 180(2): 224-235, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29193019
2.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
N Engl J Med
; 372(10): 944-53, 2015 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25738670
3.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899778
4.
Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Front Oncol
; 13: 1138683, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37007128
5.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood
; 114(6): 1166-73, 2009 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-19470696
6.
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.
Biology (Basel)
; 9(2)2020 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32050707
7.
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
J Clin Oncol
; 27(36): 6086-93, 2009 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-19858394
Resultados
1 -
7
de 7
1
Próxima >
>>